Vivos Therapeutics, Inc. (VVOS) Misses Q2 EPS by 1c

Vivos Therapeutics, Inc. (NASDAQ: VVOS) reported Q2 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $3.4 million versus the consensus estimate of $4.42 million.

For earnings history and earnings-related data on Vivos Therapeutics, Inc. (VVOS) click here.

You May Also Be Interested In

• Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
• Ennis (EBF) Reports In-Line Q1 EPS
• Keurig Dr Pepper coffee chief to depart ahead of planned split